Search | Clinical Trials Finder

Conditions: Hepatitis C Infection, Viruses, Hepatocellular Carcinoma, Hepatitis, Viral, Human, Liver Cirrhosis
Interventions: Civacir® 10%; Biological
Lead sponsor: Biotest Pharmaceuticals Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 23
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 15 more

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 794 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 40
States / cities: Hot Springs, Arkansas • Encinitas, California • Fullerton, California + 35 more

Conditions: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor
Interventions: XmAb541; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 15 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 17
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 14 more

Conditions: Primary Immunodeficiency
Interventions: Gamunex-C, IVIG-PEG; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • North Palm Beach, Florida • South Bend, Indiana + 6 more

Conditions: Pemphigus
Interventions: Ofatumumab, Acetaminophen/paracetamol, Antihistamine (cetirizine or equivalent), Prednisone/Prednisolone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Los Angeles, California • Ann Arbor, Michigan

Conditions: Dry Eye Disease
Interventions: GRF312 5%, Placebo Comparator; Drug · Other
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 10
States / cities: Glendale, California • Grove, California • Newport Beach, California + 7 more

Conditions: Rheumatoid Arthritis
Interventions: Natrunix, Placebo; Drug
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 26
States / cities: Covina, California • Encino, California • Rancho Mirage, California + 19 more

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Immune globulin (human) 10% solution for intravenous administration; Biological
Lead sponsor: Kedrion S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: Stamford, Connecticut • Miami, Florida • Tampa, Florida + 2 more

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 44
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 37 more

Conditions: Hereditary Angioedema
Interventions: CSL312, Placebo; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 12 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 8
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 5 more

Conditions: Healthy Volunteers
Interventions: ALTB-268, Placebo; Biological · Other
Lead sponsor: AltruBio Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Anti-Hepatitis A Antibody Levels in Heathy Subjects
Interventions: Immune Globulin (Human); Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Primary Immune Deficiency Disease
Interventions: Flebogamma 5% DIF; Biological
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 7
States / cities: St. Petersburg, Florida • Atlanta, Georgia • Chicago, Illinois + 4 more

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 21
States / cities: Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 17 more

Conditions: Locally Advanced or Metastatic Breast Cancer
Interventions: Phesgo, Giredestrant, Docetaxel, Paclitaxel, LHRH Agonist, Optional Endocrine Therapy of Investigator's Choice; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 922 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 10
States / cities: Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 7 more

Conditions: Uveitis, JIA
Interventions: Adalimumab, Placebo; Biological · Other
Lead sponsor: Nisha Acharya; Other
Eligibility: 2 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 11
States / cities: Sacramento, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: rituximab, melphalan, Stem Cell, Sargramostim (GM-CSF), 90Y-Zevalin, 111In Zevalin; Biological · Drug · Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lupus Erythematosus, Systemic, Lupus
Interventions: MEDI-545, Placebo; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 22
States / cities: Anniston, Alabama • Huntington Beach, California • Upland, California + 19 more

Conditions: Ischemic Stroke
Interventions: Privigen, Normal Saline; Biological · Other
Lead sponsor: Inova Health Care Services; Other
Eligibility: 45 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Primary Immune Deficiency Disorders (PIDD)
Interventions: Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]; Biological
Lead sponsor: ADMA Biologics, Inc.; Industry
Eligibility: 6 Years to 75 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more

Conditions: Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL), Malignant Lymphoma, Non-Hodgkin
Interventions: Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation (TLI), Rituximab, Carmustine, Etoposide, Filgrastim, Anti-thymocyte globulin (ATG), Cyclosporine, Mycophenolate mofetil (MMF), Cyclophosphamide, Acetaminophen, Diphenhydramine, Hydrocortisone, Methylprednisolone; Procedure · Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cytomegalovirus (CMV) Infection
Interventions: Cytogam; Drug
Lead sponsor: Fernanda P Silveira, MD, MS; Other
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy Volunteers
Interventions: HYQVIA; Drug
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 19 Years to 50 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Hialeah, Florida

Conditions: Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Refractory Desmoplastic Small Round Cell Tumor, Refractory Malignant Peripheral Nerve Sheath Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Rhabdomyosarcoma
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide, Fludarabine Phosphate, Lapine T-Lymphocyte Immune Globulin, Melphalan, Mycophenolate Mofetil, Tacrolimus, Thiotepa; Procedure · Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Up to 25 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).

Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks

A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers

Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)

Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)

Adalimumab in JIA-associated Uveitis Stopping Trial

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus

IVIG in Acute Ischemic Stroke: A Pilot Study

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients

A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults